[go: up one dir, main page]

HUP9903734A3 - Controlled-release pharmaceutical formulations for oral administration and method for preparing this - Google Patents

Controlled-release pharmaceutical formulations for oral administration and method for preparing this

Info

Publication number
HUP9903734A3
HUP9903734A3 HU9903734A HUP9903734A HUP9903734A3 HU P9903734 A3 HUP9903734 A3 HU P9903734A3 HU 9903734 A HU9903734 A HU 9903734A HU P9903734 A HUP9903734 A HU P9903734A HU P9903734 A3 HUP9903734 A3 HU P9903734A3
Authority
HU
Hungary
Prior art keywords
preparing
controlled
oral administration
pharmaceutical formulations
release pharmaceutical
Prior art date
Application number
HU9903734A
Other languages
English (en)
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of HUP9903734A2 publication Critical patent/HUP9903734A2/hu
Publication of HUP9903734A3 publication Critical patent/HUP9903734A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU9903734A 1995-11-21 1996-11-11 Controlled-release pharmaceutical formulations for oral administration and method for preparing this HUP9903734A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9523752.5A GB9523752D0 (en) 1995-11-21 1995-11-21 Pharmaceutical formulations
PCT/EP1996/005020 WO1997018814A1 (en) 1995-11-21 1996-11-11 Pharmaceutical formulations

Publications (2)

Publication Number Publication Date
HUP9903734A2 HUP9903734A2 (hu) 2000-03-28
HUP9903734A3 true HUP9903734A3 (en) 2000-04-28

Family

ID=10784188

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9903734A HUP9903734A3 (en) 1995-11-21 1996-11-11 Controlled-release pharmaceutical formulations for oral administration and method for preparing this

Country Status (29)

Country Link
EP (1) EP0862437A1 (hu)
JP (1) JPH10513481A (hu)
KR (1) KR19990071505A (hu)
CN (1) CN1215993A (hu)
AP (1) AP718A (hu)
AR (1) AR004335A1 (hu)
AU (1) AU709560B2 (hu)
BG (1) BG102438A (hu)
BR (1) BR9611626A (hu)
CA (1) CA2232715A1 (hu)
CO (1) CO4480020A1 (hu)
CZ (1) CZ155498A3 (hu)
GB (1) GB9523752D0 (hu)
HR (1) HRP960554A2 (hu)
HU (1) HUP9903734A3 (hu)
IS (1) IS4706A (hu)
MA (1) MA26410A1 (hu)
MX (1) MX9804008A (hu)
NO (1) NO982302L (hu)
NZ (1) NZ322053A (hu)
OA (1) OA10687A (hu)
PE (1) PE22898A1 (hu)
PL (1) PL326981A1 (hu)
SK (1) SK63098A3 (hu)
TN (1) TNSN96141A1 (hu)
TR (1) TR199800902T2 (hu)
WO (1) WO1997018814A1 (hu)
YU (1) YU62096A (hu)
ZA (1) ZA969722B (hu)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
ES2258300T3 (es) * 1997-12-16 2006-08-16 Pfizer Products Inc. Combinacion de antagonistas del receptor alfa-1-adrenergico y un inhibidor gmpc pdev para el tratamiento de la impotencia.
EA003101B1 (ru) 1998-03-19 2002-12-26 Бристол-Майерз Сквибб Компани Двухфазная система доставки с регулируемым высвобождением для фармацевтических средств с высокой растворимостью и способ лечения диабета с помощью этой системы
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
EP0987020A1 (en) * 1998-09-04 2000-03-22 Pharma Pass LLC Metoprolol composition and processes for manufacturing the same
EP0974343B1 (en) * 1998-07-22 2004-09-29 Pharma Pass II LLC Process for manufacturing a solid metoprolol composition
CO5140079A1 (es) * 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
UA67802C2 (uk) * 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. Фармацевтична композиція з контрольованим вивільненням інгібітора цгмф фде-5 (варіанти), спосіб її одержання та спосіб лікування еректильної дисфункції
US20030059467A1 (en) * 2001-09-14 2003-03-27 Pawan Seth Pharmaceutical composition comprising doxasozin
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2005037247A2 (en) * 2003-10-17 2005-04-28 Ranbaxy Laboratories Limited Oral matrix formulations of doxazosin
US20050255157A1 (en) * 2004-05-11 2005-11-17 Glenmark Pharmaceuticals Limited Sustained release, mucoadhesive vaginal pharmaceutical compositions
KR100574554B1 (ko) * 2004-05-28 2006-04-27 한미약품 주식회사 니아신의 경구투여용 서방성 조성물
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
KR100679111B1 (ko) * 2004-11-20 2007-02-07 대우약품공업주식회사 독사조신을 포함하는 서방성 정제
AU2006284053B2 (en) * 2005-08-22 2010-04-22 Novartis Ag Pharmaceutical compositions comprising a pH-dependent drug, a pH modifier and a retarding agent
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US7722898B2 (en) 2006-04-26 2010-05-25 Supernus Pharmaceuticals, Inc. Modified-release preparations containing oxcarbazepine and derivatives thereof
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
KR101452915B1 (ko) 2006-05-04 2014-10-21 베링거 인겔하임 인터내셔날 게엠베하 다형태
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN100396282C (zh) * 2006-07-25 2008-06-25 山东省医药工业研究所 甲磺酸多沙唑嗪缓释胶囊及制备方法
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
WO2009114648A1 (en) 2008-03-11 2009-09-17 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101004205B1 (ko) 2008-12-17 2010-12-24 동아제약주식회사 유데나필 함유 서방성 제제를 제조하기 위한 제어방출 조성물
PT2395983T (pt) 2009-02-13 2020-07-03 Boehringer Ingelheim Int Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dp-iv e opcionalmente um agente antidiabético adicional e suas utilizações
AR076341A1 (es) 2009-04-20 2011-06-01 Elcelyx Therapeutics Inc Terapias basadas en ligados de receptores quimiosensoriales. metodo de tratamiento. composicion
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
KR20120107080A (ko) 2009-11-27 2012-09-28 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
KR101927068B1 (ko) 2010-05-05 2018-12-10 베링거 인겔하임 인터내셔날 게엠베하 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법
MY161846A (en) 2010-07-09 2017-05-15 James Trinca Green Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
SG189444A1 (en) 2010-10-19 2013-05-31 Elcelyx Therapeutics Inc Chemosensory receptor ligand-based therapies
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
SI2661266T1 (sl) 2011-01-07 2021-01-29 Anji Pharma (Us) Llc Terapije, na osnovi kemosenzoričnih receptorskih ligandov
CN102058555A (zh) * 2011-01-13 2011-05-18 北京汇诚瑞祥医药技术有限公司 一种多沙唑嗪控释片
UY33937A (es) 2011-03-07 2012-09-28 Boehringer Ingelheim Int Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
CN102188431A (zh) * 2011-05-09 2011-09-21 浙江九旭药业有限公司 甲磺酸多沙唑嗪缓释片及其制备方法
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
WO2013171166A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
JP6224084B2 (ja) 2012-05-14 2017-11-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
WO2014197744A1 (en) 2013-06-05 2014-12-11 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
CN105616378A (zh) * 2014-10-31 2016-06-01 康普药业股份有限公司 一种氟康唑胶囊及其制备方法
MX390363B (es) 2016-06-10 2025-03-20 Boehringer Ingelheim Int Combinacion de linagliptina y metformina
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1198386B (it) * 1982-07-06 1988-12-21 Lepetit Spa Un prodotto a rilascio protratto contenente il suloctidile
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4837111A (en) * 1988-03-21 1989-06-06 Alza Corporation Dosage form for dispensing drug for human therapy
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
MX9100277A (es) * 1990-07-23 1992-02-28 Alza Corp Dispositivo osmotico oral para aplicar nicotina

Also Published As

Publication number Publication date
CA2232715A1 (en) 1997-05-29
NO982302D0 (no) 1998-05-20
BR9611626A (pt) 1999-06-01
ZA969722B (en) 1998-05-20
MX9804008A (es) 1998-09-30
IS4706A (is) 1998-03-31
PL326981A1 (en) 1998-11-09
NZ322053A (en) 1999-11-29
JPH10513481A (ja) 1998-12-22
AU709560B2 (en) 1999-09-02
HUP9903734A2 (hu) 2000-03-28
CN1215993A (zh) 1999-05-05
KR19990071505A (ko) 1999-09-27
MA26410A1 (fr) 2004-12-20
WO1997018814A1 (en) 1997-05-29
GB9523752D0 (en) 1996-01-24
NO982302L (no) 1998-07-17
CO4480020A1 (es) 1997-07-09
AP718A (en) 1999-01-06
SK63098A3 (en) 1999-05-07
BG102438A (en) 1999-01-29
AU7572196A (en) 1997-06-11
CZ155498A3 (cs) 1999-03-17
PE22898A1 (es) 1998-05-07
OA10687A (en) 2002-11-27
TR199800902T2 (xx) 1998-09-21
YU62096A (sh) 1999-03-04
AP9600883A0 (en) 1997-01-31
EP0862437A1 (en) 1998-09-09
TNSN96141A1 (fr) 2005-03-15
HRP960554A2 (en) 1998-02-28
AR004335A1 (es) 1998-11-04

Similar Documents

Publication Publication Date Title
HUP9903734A3 (en) Controlled-release pharmaceutical formulations for oral administration and method for preparing this
PL322579A1 (en) 2-methyl-thiene-benzodiazeoin prparation for oral administration
IL117041A0 (en) Oral pharmaceutical dosage form
PL314731A1 (en) S(+)-ibuprofen preparations for oral administration
HUP0004050A3 (en) Itraconazole exhibiting improved solubility, a method of preparing the same and pharmaceutical composition for oral administration comprising the same
IL115097A0 (en) Pharmaceutical compositions adapted for oral administration
HUP0203374A3 (en) Sold oral pharmaceutical composition and process for its preparation
EP0919228A4 (en) CAPSULES FOR ORAL PREPARATIONS AND CAPSULE PREPARATIONS FOR ORAL ADMINISTRATION
HUP9903407A3 (en) Oral pharmaceutical preparation containing ibandronat
GB9518953D0 (en) Pharmaceutical formulations
IL126271A0 (en) 2-Arylpyrazolisoquinoline and cinnolinone derivatives methods for their preparation and pharmaceutical formulations containing them
HUP0104687A3 (en) Methods for preparing coated drug particles and pharmaceutical formulations thereof
PL314732A1 (en) S(+)-ethodolac preparations for oral administration
HUP9800573A3 (en) Rapamycin formulations for oral administration and process for their preparation
HU9402785D0 (en) Paramycin formulations for oral administration
PL307469A1 (en) Preparation for oral administration
AU4400996A (en) Solid formulations for oral administration of cyclosporine a
IL114673A (en) Pharmaceutical compositions containing protein for oral administration
EP0953359A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
AU5347996A (en) Preparation for oral administration
HUP9801947A3 (en) Device and process for mixing a pharmaceutical composition with another agent and method for oral administration of the pharmaceutical preparation
AU1066897A (en) Pharmaceutical preparations for oral administration and process for their production
AU3860797A (en) Pharmaceutical formulations for oral administration
IL136635A0 (en) Pharmaceutical formulations and processes for their preparation
HUP0101012A3 (en) Pharmaceutical composition for oral administration